Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials

@article{Xu2019SafetyAT,
  title={Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine – a meta-analysis of randomized controlled trials},
  author={Da Xu and Deng Chen and Lina Zhu and Ge Tan and Haijiao Wang and Yu Zhang and Ling Liu},
  journal={Cephalalgia},
  year={2019},
  volume={39},
  pages={1164 - 1179}
}
Aim To systematically evaluate the safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies from the results of randomized controlled trials. Methods Online databases were searched on calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine. Overall withdrawal, withdrawal due to adverse events, adverse events, serious adverse events and specific adverse events were extracted from the included studies. A meta-analysis… 

Figures and Tables from this paper

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

The current body of evidence reveals that CGRP mAb is an effective and safe preventive treatment for episodic migraine.

Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis

Most drugs performed similarly and were superior to placebo in most of the authors' analyses, and further head-to-head research on different types of CGRP monoclonal antibodies is necessary to validate the present findings.

Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials

Use of galcanezumab is related to a significantly reduced monthly headache frequency compared with placebo for the treatment of migraine and episodic cluster headache, and has the same treatment efficacy with 240 mg group whilerelated to a lower risk for adverse effects for the Treatment of migraine.

Galcanezumab for the Management of Migraine: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

Galcanezumab is clinically safe and efficient for the management of migraine, and the use of a higher dose increases its efficacy, according to a systematic review and meta-analysis of all randomized placebo-controlled trials evaluated.

Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: A systematic review and meta‐analysis

It is proposed that eptinezumab is generally effective and safe for the preventive treatment of episodic or chronic migraine.

The role of erenumab in the treatment of migraine

Clinical trials data suggest superiority of the CGRP mAbs to placebo to placebo in terms of prevention of migraine symptoms, migraine-specific quality of life and headache related disability.

Recent Advances in Pharmacotherapy for Episodic Migraine

Episodic migraine treatment is reviewed and, as experience with monoclonal antibodies grows in clinical practice, an evolution in migraine management can be expected to take shape.

Drug interactions and risks associated with the use of triptans, ditans and monoclonal antibodies in migraine

Current evidence concerning potential risks and interactions associated with concomitant use of drugs indicated for the abortive treatment of migraine, namely triptans and ditans, and more recently developed drugs used for the preventive treatment is reviewed.

Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults.

Evidence is presented to support the safe and effective use of Eptinezumab-jjmr, a humanized monoclonal specific to CGRP for the prevention of migraines in adults, and the science and mechanism of action, indication and clinical evidence for use.

References

SHOWING 1-10 OF 40 REFERENCES

Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab

Global results so far obtained point to erenumab as a new promising candidate for the preventative treatment of episodic migraine as well as a favorable safety profile as demonstrated by the lack of significant differences in the occurrence of adverse events.

Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies

All four CGRP antibodies display comparable efficacy that does not differ significantly from that of the currently available oral antimigraine drugs, however, their safety and tolerability profiles as well as low frequency of administration looks promising but remains to be verified in long-term and large-scale trials.

Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

Galcanezumab 120 or 240 mg given once monthly was efficacious, safe, and well tolerated and both doses were superior to placebo for all key secondary endpoints.

Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial